ArticleInternational journal of molecular sciences2020
Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 31 citations in OpenAlex.
- Novel Co-Occurrence of GermlineInternational journal of molecular sciences · 2026Article
- ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.Cancer chemotherapy and pharmacology · 2026Review
- ALK-tyrosine kinase inhibitor resistance due to acquiredTranslational lung cancer research · 2026Article
- Case report: ALK inhibitor-induced transformation of ALK fusion-positive lung adenocarcinoma to large cell neuroendocrine carcinoma.NPJ precision oncology · 2026Article
- New advances in understanding the mechanisms and treatment challenges of ALK-targeted therapy resistance in lung cancer.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Histologic transformation of non-small-cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms.Cancer science · 2024Review
- Alectinib continuation beyond progression inTranslational lung cancer research · 2024Article
- Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De NovoInternational journal of molecular sciences · 2023Article
- HighMedicina (Kaunas, Lithuania) · 2023Article
- Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review.Translational lung cancer research · 2023Review
- Crosstalk between endoplasmic reticulum stress and multidrug-resistant cancers: hope or frustration.Frontiers in pharmacology · 2023Review
- Targeted therapies in non-small cell lung cancer: present and future.Faculty reviews · 2023Review
- Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors.Cancers · 2022Article
- Research progress regarding long-chain non-coding RNA in lung cancer: a narrative review.Journal of thoracic disease · 2022Review
- Durable clinical response to ALK tyrosine kinase inhibitors inTranslational cancer research · 2022Article
- Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma.Frontiers in oncology · 2022Article
- The quantum leap in therapeutics for advancedFrontiers in oncology · 2022Article
- Review
- A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.Thoracic cancer · 2021Article
- Complex genetic alterations contribute to rapid disease progression in anTranslational cancer research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.